Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 16/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649536 | 0.87 | CRHR1 (0.41) | CRHR1HSD11B1C5AR1 | |
| SCHEMBL648698 | 0.87 | C5AR1 (0.56) | CRHR1HSD11B1C5AR1 | |
| SCHEMBL14572836 | 0.85 | CRHR1 (0.49) | CRHR1C5AR1BCHETSHR | |
| SCHEMBL14607057 | 0.84 | CRHR1 (0.49) | CRHR1C5AR1BCHETSHR | |
| SCHEMBL648994 | 0.84 | CRHR1 (0.44) | CRHR1C5AR1BCHETSHR | |
| SCHEMBL5135611 | 0.84 | CRHR1 (0.49) | CRHR1C5AR1TSHR | |
| SCHEMBL649846 | 0.83 | C5AR1 (0.47) | CRHR1HSD11B1C5AR1BCHETSHR | |
| SCHEMBL649792 | 0.82 | C5AR1 (0.62) | CRHR1C5AR1TSHR | |
| SCHEMBL1913039 | 0.81 | CRHR1 (0.47) | CRHR1C5AR1TSHR | |
| SCHEMBL650398 | 0.81 | CRHR1 (0.48) | CRHR1C5AR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |